70
Participants
Start Date
March 11, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
May 31, 2028
AST-201
AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
RECRUITING
National Cancer Center, Korea, Gyeonggi-do
RECRUITING
CHA Bundang Medical Center, Seongnam
RECRUITING
Severance Hospital, Seoul
RECRUITING
Samsung Medical Center, Seoul
Lead Sponsor
CHA University
OTHER
National Cancer Center, Korea
OTHER_GOV
Samsung Medical Center
OTHER
Severance Hospital
OTHER
Aptamer Sciences, Inc.
INDUSTRY